Climb Bio, Inc.
CLYM
$1.21
-$0.02-1.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -146.92% | 5.39% | 83.79% | -3,134.47% | 53.39% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.78% | -53.92% | -94.92% | 9,985.33% | -59.31% |
| Change in Net Operating Assets | 135.11% | 227.25% | -166.36% | 409.38% | -145.04% |
| Cash from Operations | -179.55% | 26.92% | -1,032.68% | 63.33% | -92.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 19.96% | 25.60% | -1,335.78% | -136.36% | -62.58% |
| Cash from Investing | 19.96% | 25.60% | -644.31% | -170.14% | -62.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -87.19% | -98.23% | 855,913.33% | -94.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -98.19% | -98.23% | 855,913.33% | -94.79% |
| Foreign Exchange rate Adjustments | 57.89% | -152.78% | 468.42% | 167.86% | 91.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.25% | 23.41% | -165.16% | 890.93% | -66.67% |